Results of Switching From Tofacitinib to Upadacitinib in Patients With Atopic Dermatitis: A Retrospective Medical Record Review

Abstract

in EMCD 2,4,5 and immune complexes consisting of IgM, IgA, C3, and fibrin deposited in cutaneous vasculature found in EM. 4 Limitations of this systematic review include small sample sizes, lack of high-quality randomized controlled trials, and lack of follow-up data. In addition, confirmation of EMCD in all included cases is difficult to determine. However, positive patch testing confirmed 95.1% (n = 116/122) of allergens, EM-like histology was confirmed by biopsy in 92.7% (n = 38/41) of patients, and targeted lesions were reported in 78.5% (n = 84/107) of patients. Despite these limitations, our findings provide important conclusions to guide EMCD management, showing that 99.0% cases (n = 98/99) of EMCD achieved CoR with allergen withdrawal or allergen withdrawal and corticosteroids.

Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study

“…Safety and effectiveness of upadacitinib have been shown in clinical trials, but real-world data are currently limited [18,[20][21][22][23][24]. This prospective, multicentric study provides insights into the short-term safety and effectiveness of 30 mg upadacitinib in the treatment of moderate-to-severe adult AD patients in a real-world setting.…”

Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry

“…Daily practice data of upadacitinib effectiveness in AD is promising, but scarce. Only three clinical daily practice studies and a few case series/reports have been published 10–23 . Moreover, daily practice data of the effectiveness of upadacitinib on HE in AD patients has not been published.…”

Upadacitinib effectiveness in moderate‐to‐severe atopic dermatitis: A real‐life multicentre and retrospective study

“…6 However, research works showing real-life experience are scarce. 3,[7][8][9][10] Thus, this study aimed to describe mid-term effectiveness and safety of upadacitinib in a daily practice setting.…”

“…Upadacitinib has shown also the highest short‐term efficacy rates in recent metanalyses 6 . However, research works showing real‐life experience are scarce 3,7‐10 . Thus, this study aimed to describe mid‐term effectiveness and safety of upadacitinib in a daily practice setting.…”